Home "PharmaSource"

Day One - 24 March

Chair: Mike Chace-Ortiz, Sr. Director, Product Strategy, API Intelligence, Thomson Reuters

09:25 – 09:55 Global Pharma Sourcing and Contracting 2010 – The Megatrends

• Reviewing the latest strategic alliance, mergers, acquisition and licensing agreements
• Emerging market sourcing – has it lost its appeal?
• Big Pharma – the new contract manufacturer?
• Evaluating the impact of the rise of the Generics and the implications for Big Pharma sourcing
• Analysing the latest demand trends and the impact on your procurement departments
Johnathon Marshall, Director, Pharmaceutical Operations, PricewaterhouseCoopers
 

09:55 – 10:10 Deal Making – The Life Blood of the Generic Industry – The Megatrends Part II

• What are the key drivers for deal making in the generic industry?
• Deal making as means to ensure access to active ingredients
• Pros and cons of backward integration
• Deal making and generic biologics – what to expect?
Mike Chace-Ortiz, Sr. Director, Product Strategy, API Intelligence, Thomson Reuters
 

10:10 – 10:50 From Tactical to Strategic – The Evolution of Pharma Outsourcing

• Overcoming short-time supply problems – will there always be a role for tactical partners?
• Evaluating the long-term cost advantages and resource management benefits of strategic sourcing
• Efficiently integrating new partners in to your internal manufacturing network
• Can and should tactical partners become strategic partners?
Dr. Michael Herrmann, R&D Outsourcing Manager, International R&D Outsourcing, Nycomed
 

10:50 – 11:30 Big Pharma Insights –  Exploring the Desire to Build Global Supply Bases
• Building & maintaining an effective global supply base
• Strategically consolidating the number of suppliers to create leverage for both parties
• Key strategic requirements for the supply base
• Balancing established and emerging market suppliers to minimise risks to your supply chain
Dr. Kevan Reeve, Global Category Lead, Process Chemicals & Excipients, Global External Sourcing, AstraZeneca
 

11:30 -12:00 Refreshment & Networking

12:00 - 13:00 Roundtables

13:00 – 14:00 Networking Lunch

14:00 – 14:40 Sourcing Criteria and Metrics Used by Big Pharma to Select Their Partners and Suppliers
• What drives Big Pharma to select their partners and suppliers?
• Evaluating the importance of: the speed of project turn around, reputation, and IP protection
• It’s not just about the price – exploring the strategic factors that influence their decision
• Size and capacity – What is the optimum balance?
Dr. James Tornos, Associate Director, Science Services, Outsourcing & Procurement, Pfizer
 

14:40 – 15:20  Achieving Sustainable Chemical Development and Procurement Excellence
• Ensuring the reliable supply of critical raw materials
• Guaranteeing that SHE compliance is achieved when sourcing from emerging markets
• Analysing the selection criteria used to successfully select the right set of suppliers
• Establishing effective communications between development chemists and procurement specialists
John J. Haefele, Global Category Manager Chemicals, Global Strategic Procurement, F. Hoffmann – La Roche  
 

15:20 – 15:50 Refreshment & Networking

15:50 - 16:50 Workshops

16:50-17:00 Chairman’s Closing Remarks

17:00-18:00 Networking Drinks Reception